Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Lee Joon Sup reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc reported that director Lee Joon Sup received an equity award of 1,803 ordinary shares in the form of restricted stock units. These units were granted at no cash cost and will vest on the one-year anniversary of the award date. Following this grant, Lee directly holds 1,803 ordinary shares.
Jellison William R reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director William R. Jellison received an equity award of 1,444 ordinary shares at a price of $0.00 per share. This reflects a grant or award, not an open-market purchase. Following the award, he directly owns 6,444 ordinary shares.
According to the footnote, the grant represents restricted stock units that vest on the one-year anniversary of the award date, tying the compensation to continued service over that period.
Medtronic plc director Randall J. Hogan reported routine equity compensation activity. He received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date. In a related move, 207 shares were withheld to cover tax obligations when previously granted restricted stock units vested, rather than being sold on the open market. Following these transactions, he directly holds 48,998 ordinary shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Groetelaars John P reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director John P. Groetelaars received a stock award rather than buying shares on the market. He was granted 1,444 ordinary shares on a Form 4 report, at a stated price of $0.00 per share, as compensation.
The award represents restricted stock units that vest on the one-year anniversary of the grant date, so he must remain eligible through that period to receive the shares. Following this grant, his directly held position reported in this filing is 1,444 ordinary shares, reflecting a small, routine equity award for a board member.
Medtronic plc director Lidia Fonseca reported routine equity compensation activity. She received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date.
Upon vesting of previously granted restricted stock units, 207 shares were withheld to cover taxes at a price of $81.90 per share. After these transactions, she directly owns 7,644 Medtronic ordinary shares, which includes 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Scott C. Donnelly reported routine equity compensation activity. He received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted units vested, 207 shares were withheld at $81.90 per share to cover related tax obligations, rather than being sold on the market. Following these transactions, he directly holds 23,679 Medtronic ordinary shares, including 145 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Craig Arnold reported routine equity compensation activity involving the company’s ordinary shares. He received an award of 2,111 restricted stock units that vest on the one-year anniversary of the award date, increasing his direct holdings.
When previously granted restricted stock units vested, 207 shares were withheld to cover taxes, a non-market disposition used for tax payment rather than an open-market sale. Following these transactions, he directly owned 42,185 shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Medtronic PLC reports that Vanguard Capital Management beneficially owned 96,424,044 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole power to dispose of 96,424,044 shares and sole voting power for 13,090,211 shares. The disclosure attributes holdings to Vanguard Capital Management LLC and specified affiliates and was signed on 04/28/2026.
Medtronic plc reported that an unauthorized third party accessed data in certain corporate IT systems. After discovering the issue, the company contained the incident, activated its response protocols, and brought in external cybersecurity experts to investigate and remediate.
Medtronic states it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or its ability to meet patient needs. Based on current findings, it does not expect a material impact on its business or financial results. The company is assessing whether personal information was accessed and will notify and support affected individuals as needed.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A regarding Medtronic PLC common stock, reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.